Heterotopic intra-abdominal cardiac transplantation was performed following the method of Corry and coworkers (25 (link)). Briefly, the donor aorta and pulmonary artery were anastomosed to the recipient abdominal aorta and inferior vena cava in the peritoneal cavity. Graft survival was monitored daily by abdominal palpation and graft rejection confirmed visually by laparotomy. At the time of cardiac graft recovery, 10 mL of Ringer’s solution was flushed into the recipient circulatory system. Graft pieces and recipient spleens were removed and were snap-frozen in liquid nitrogen or placed in media for digestion and analyses of graft-infiltrating cells. Some allograft recipients were given 250 μg anti-CD154 mAb (MR-1, BioXCell, West Lebanon, NH) or control rat IgG (Sigma-Aldrich, St. Louis, MO) i.p. on days 0 and 1 post-transplant.
Anti cd154 mab mr 1
Manufactured by BioXCell
Anti-CD154 mAb (MR-1) is a monoclonal antibody that binds to the CD154 (also known as CD40 ligand) protein. CD154 is a key regulator of immune responses and plays a role in various inflammatory and autoimmune processes.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using anti cd154 mab mr 1
1
Heterotopic Cardiac Transplantation Protocol
2
Modulation of T Cell Responses in Heart Allograft
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Rabbit anti‐mouse thymocyte serum was generated by the Hybridoma Core at the Cleveland Clinic Lerner Research Institute as previously described.4 Heart allograft recipients were treated with mATG (0.5 mg i.p.) on days 0 and 4 posttransplant, and non‐transplanted mice were injected with 0.5 mg mATG i.p. on days 0 and 4 of the experiment. For CD4 T cell depletion, anti‐mouse CD4 mAb (clones GK1.5 and YTS191, BioXCell) were injected i.p. on days −3, −2, −1 relative to mATG treatment, 200 μg each per animal per day. When indicated, the recipients were treated i.v. with 1 mg anti‐CD154 mAb MR1 1 day prior to the surgery or with 0.1 mg agonistic anti‐CD40 mAb FGK4.5 on days 0 and 1 posttransplant (both from BioXCell). For the administration of synthetic Mincle agonist, non‐transplanted B6 mice treated with 0.5 mg mATG on days 0 and 4 were additionally injected with trehalose‐6,6‐dibehenate (TDB, InvivoGen) at 4 mg/kg i.p. twice weekly for the experiment duration starting on day 2.
3
Modulating Immune Responses in Heart Transplantation
4
Allogeneic Bone Marrow Transplant with Dual Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
BALB/c recipient mice underwent nonmyeloablative total body irradiation (TBI, 3 Gy) prior to the intravenous injection of 20À25 Â 10 6 whole bone marrow cells (BMCs) derived from fully allogeneic B6 or AKR donor mice. Following BMT, recipient mice were treated with a combination therapy consisting of intravenous injection of 1 mg/kg lipo-aGC and intraperitoneal injection of 0.5 mg anti-CD154 mAb (MR1; BioXcell, West Lebanon, NH), referred to as ''our regimen'' below. For Treg depletion, 1 mg anti-CD25 mAb (PC61.5.3; BioXcell) was administered by intraperitoneal injection. In some experiments, the recipient thymus was removed 2 weeks before BMT.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!